Benjamin Caulier
- Postdoc; PhD, Msc
- +47 22 78 23 19
Scientia fellow II/Kreftforeningen
Education:
2014-2017: PhD in Biotechnology, Development of a non-integrative (protein vector) for the generation of clinical-grade induced pluripotent stem cells, Univ. Grenoble Alpes, TIMC-IMAG CNRS 5525, French Blood Bank, Grenoble, France
2015-2016: Label Research: Business, Industry & Innovation, Univ. Grenoble Alpes, Grenoble, France
2011-2013: Master degree in Molecular & Cell Biology, Specialty: Immunology, Microbiology & Infectiology, University Joseph Fourier, Grenoble, France
2010-2011: Bachelor degree in Engineering Sciences & Technology, Specialty: Risk Management, Quality Assurance & Environment, IRIAF, Niort, France
2008-2010: Undergraduate in Biology (DUT), Specialty: Environment
Research interests/projects:
Cancer immunotherapy, novel cellular strategies (development of CARs, TCR redirected cells), biotechnological engineering, induced pluripotent stem cells-based modeling
Work experience:
2020-Present: Postdoc, Development of CAR therapy, Department of Cellular Therapy, OUS-Radiumhospitalet, Oslo, Norway
2017-2019: Postdoc, Development of a therapeutic type-3 adenoviral-like particle (dodecamer) for the treatment of acute myeloid leukemia. Departments of Cellular Hematology & Pediatric Oncology, Grenoble Alpes Hospital, Institute for Advanced Biosciences, TIMC-IMAG, Univ. Grenoble Alpes, Grenoble, France
2014-2017: PhD student, Development of a non-integrative (protein vector) for the generation of clinical-grade induced pluripotent stem cells. TIMC-IMAG CNRS 5525, Team Experimental Recombinant Therapy, French Blood Bank, Univ. Grenoble Alpes, Grenoble, France
2012-2013: Intern, Induction of patient-specific cytotoxic T lymphocytes against non-small cell lung cancer (NSCLC) with a therapeutic allogeneic plasmacytoid dendritic cell line (vaccine). Institute for Advanced Biosciences INSERM U1209, Team Immunobiology & Cancer Immunotherapy, French Blood Bank, Univ. Grenoble Alpes, Grenoble.
2011-2012: Intern, Induction of cytotoxic T lymphocytes against viruses & melanoma cancer with a therapeutic allogeneic plasmacytoid dendritic cell line (vaccine). Institute for Advanced Biosciences INSERM U1209, Team Immunobiology & Cancer Immunotherapy, French Blood Bank, Univ. Grenoble Alpes, Grenoble.
Publications 2022
Recombinant Transcription Factors (TFs) Fused to ZEBRA Minimal Transduction Domain (MD) for Modulation of mRNA Transcripts
Methods Mol Biol, 2383, 275-291
DOI 10.1007/978-1-0716-1752-6_19, PubMed 34766297
How CAR T Cells Breathe
Cells, 11 (9)
DOI 10.3390/cells11091454, PubMed 35563759
Publications 2021
Pharmacologic Control of CAR T Cells
Int J Mol Sci, 22 (9)
DOI 10.3390/ijms22094320, PubMed 33919245
Publications 2020
Evaluation of the human type 3 adenoviral dodecahedron as a vector to target acute myeloid leukemia
Mol Ther Methods Clin Dev, 20, 181-190
DOI 10.1016/j.omtm.2020.11.009, PubMed 33473357
Publications 2017
Targeted release of transcription factors for human cell reprogramming by ZEBRA cell-penetrating peptide
Int J Pharm, 529 (1-2), 65-74
DOI 10.1016/j.ijpharm.2017.06.073, PubMed 28647433
Publications 2016
Targeted release of transcription factors for cell reprogramming by a natural micro-syringe
Int J Pharm, 513 (1-2), 678-687
DOI 10.1016/j.ijpharm.2016.09.081, PubMed 27697633